<DOC>
	<DOCNO>NCT02616562</DOCNO>
	<brief_summary>This trial conduct globally . The aim trial investigate efficacy safety once-weekly NNC0195-0092 treatment compare daily growth hormone treatment ( Norditropin® FlexPro® ) growth hormone treatment naïve pre-pubertal child growth hormone deficiency . The main trial period consist 26 week treatment , follow 26 week extension period 104 week safety extension trial period .</brief_summary>
	<brief_title>Investigating Efficacy Safety Once-weekly NNC0195-0092 Treatment Compared Daily Growth Hormone Treatment ( Norditropin® FlexPro® ) Growth Hormone Treatment naïve Pre-pubertal Children With Growth Hormone Deficiency</brief_title>
	<detailed_description />
	<mesh_term>Endocrine System Diseases</mesh_term>
	<mesh_term>Dwarfism , Pituitary</mesh_term>
	<mesh_term>Hormones</mesh_term>
	<criteria>Boys : Tanner stage 1 pubic hair testis volume 4 ml , age least 2 year 26 week equal 10.0 year screen Girls : Tanner stage 1 breast development ( palpable glandular breast tissue ) pubic hair , age least 2 year 26 week equal 9.0 year screen Confirmed diagnosis GHD ( growth hormone deficiency ) within 12 month prior screen determine two different GH ( growth hormone ) stimulation test , define peak GH level equal 7.0 ng/ml . For child three pituitary hormone deficiencies one GH stimulation test need No prior exposure GH therapy and/or IGFI ( insulinlike growth factor I ) treatment Height least 2.0 standard deviation mean height chronological age ( CA ) gender accord standard Centers Disease Control Prevention 220 year : Girls/Boys statureforage weightforage percentile CDC screen Annualized height velocity ( HV ) 25th percentile CA ( chronological age ) gender 0.7 SD ( standard deviation ) score CA sex , accord standard Prader calculate time span minimum 6 month maximum 18 month Any clinically significant abnormality likely affect growth ability evaluate growth stand measurement : Chromosomal aneuploidy significant gene mutation cause medical `` syndrome '' short stature , include limited Turner syndrome , Laron syndrome , Noonan syndrome , absence GH receptor . Congenital abnormality ( cause skeletal abnormality ) , include limited RussellSilver Syndrome , skeletal dysplasia . Significant spinal abnormality include limited scoliosis , kyphosis spina bifida variant Children born small gestational age ( SGA birth weight and/or birth length below2 SD gestational age ) Concomitant administration treatment may effect growth , include limited methylphenidate treatment attention deficit hyperactivity disorder ( ADHD ) Prior history presence malignancy and/or intracranial tumour</criteria>
	<gender>All</gender>
	<minimum_age>30 Months</minimum_age>
	<maximum_age>10 Years</maximum_age>
	<verification_date>April 2017</verification_date>
</DOC>